Abstract
We report the first case of diffuse large B-cell lymphoma (DLBCL) of the stomach displaying CD20-negative relapse after rituximab-containing treatment and the re-appearance of CD20 expression at the second failure. The loss of CD20 expression in B-cell lymphomas relapsing after rituximab is a well-known phenomenon, but its actual impact in DLBCL is difficult to estimate. This paradigmatic case suggests that CD20-expression reappearance after purging of CD20-positive clones with rituximab might be an underestimated occurrence in B-cell lymphomas. Accordingly, every relapse, whenever possible, should be histologically assessed with diagnostic and immunophenotyping purposes.References
- Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res. 1999; 5(3):611-5. Google Scholar
- Haidar JH, Shamseddine A, Salem Z, Mrad YA, Nasr MR, Zaatari G. Loss of CD20 expression in relapsed lymphomas after rituximab therapy. Eur J Haematol. 2003; 70(5):330-2. Google Scholar
- Clarke LE, Bayerl MG, Ehmann WC, Helm KF. Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy. J Cutan Pathol. 2003; 30(7):459-62. Google Scholar
- Schmitz K, Brugger W, Weiss B, Kaiserling E, Kanz L. Clonal selection of CD20 negative Non-Hodgkin Lymphoma cells after treatment with anti-CD20 antibody rituximab. Br J Haematol. 1999; 106(2):571-2. Google Scholar
- Kennedy GA, Tey S-K, Cobcroft R, Marlton P, Cull G, Grimmett K. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin’s lymphoma: a retrospective review. Br J Haematol. 2002; 119(2):412-416. Google Scholar
- Micallef IN, Kirk A, Norton A, Foran JM, Rohatiner AZ, Lister TA. Peripheral T-cell lymphoma following rituximab therapy for B-cell lymphoma. Blood. 1999; 93:2427-2428. Google Scholar
- Grillo-Lopez AJ, Kunkel L. Clin Cancer Res. 2000; 6:317-318. Google Scholar
- Seliem RM, Freeman JK, Styeingart RH, Hasserjian RP. Immunophenotypic changes and clinical outcome in B-cell lymphomas treated with rituximab. Appl Immunohistochem Mol Morphol. 2006; 14(1):18-23. Google Scholar
- Coiffier B, Bouaffia F, Thieblemont C. Rituximab re-treatment in B-cell lymphoma patients: efficacy and toxicity in 59 patients treated in one center. Blood. 2002; 100(11):1390a. Google Scholar
- Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN. Treatment with ibritumomab Tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-hodgkin’s lymphoma. J Clin Oncol. 2002; 20(15):3262-3269. Google Scholar